Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dander

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    54 result(s) found for: Dander. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2012-001651-39 Sponsor Protocol Number: BIGRADE-IHR-12 Start Date*: 2012-11-14
    Sponsor Name:LOFARMA
    Full Title: In-vivo biological standardization of Dermatophagoides, Betulaceae and Graminaceae extracts for the determination of the biological activity in HEP units
    Medical condition: Respiratory allergopathy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10054928 Allergy to plants PT
    14.1 10021428 - Immune system disorders 10001742 Allergy to animal PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019373-15 Sponsor Protocol Number: 291202BS Start Date*: 2010-06-15
    Sponsor Name:Marinomed Biotechnologie GmbH
    Full Title: A phase IIa, single-center, randomized, reference-controlled, observer-blind trial to assess the efficacy of a topical Aescin formulation in experimentally induced itch, wheal and flare reactions i...
    Medical condition: subjects with proven type I allergy against one of the three allergens: grass pollen, tree pollen, cat epithelia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036019 Pollen allergy LLT
    12.1 10066093 Birch pollen allergy LLT
    12.1 10001742 Allergy to animal LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004745-18 Sponsor Protocol Number: FFR30008 Start Date*: 2005-03-17
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of once-daily, intranasal administration of GW685698X Aqueous Nasal Spray 50mcg...
    Medical condition: Perennial Allergic Rhinitis
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002771-40 Sponsor Protocol Number: PIX-01 Start Date*: 2006-08-28
    Sponsor Name:S.G.O. Johansson, MD PhD Professor
    Full Title: Importance of IgE antibody fraction size on allergen sensitivity of basophils from cat allergic patients on Xolair. A pilot study.
    Medical condition: Allergic asthma and or rhinitis due to allergy to cat dander
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004493-25 Sponsor Protocol Number: FFR106080 Start Date*: 2006-01-12
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg...
    Medical condition: Perennial Allergic Rhinitis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) LV (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004916-79 Sponsor Protocol Number: SMART_10 Start Date*: 2013-02-26
    Sponsor Name:Lofarma S.p.A.
    Full Title: Efficacy and Safety of sublingual immunotherapy with Allergoid LAIS® Grass tablets for patients with grass pollen-induced allergic rhinoconjunctivitis, a phase III study
    Medical condition: Patients suffering from allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003572-19 Sponsor Protocol Number: V00114 CP 302 2A Start Date*: 2007-12-04
    Sponsor Name:Pierre Fabre Médicament
    Full Title: EFFICACY AND SAFETY STUDY OF THE ANTIHISTAMINE V0114CP 2.5MG IN THE TREATMENT OF PERENNIAL ALLERGIC RHINITIS. RANDOMISED, DOUBLE-BLIND, THREE ARM PARALLEL GROUP STUDY INCLUDING PLACEBO AND ACTIV...
    Medical condition: The intended indication for the product under development is the treatment of perennial allergic rhinitis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Prematurely Ended) LT (Prematurely Ended) CZ (Completed) GB (Prematurely Ended) ES (Completed) FI (Prematurely Ended) LV (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000211-26 Sponsor Protocol Number: D5890L00007 Start Date*: 2004-08-04
    Sponsor Name:AstraZeneca AB
    Full Title: A comperative, placebo-controlled, doubleblind, double dummy, cross over, single center phase IIIb study between formoterol alone and the fixed combination of formoterol and budesonide on airway re...
    Medical condition: Patient with stable and mild allergic asthma.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004891-31 Sponsor Protocol Number: FFR110537 Start Date*: 2016-08-03
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110mcg in Adults and Adolesc...
    Medical condition: Rhinitis, Allergic, Perennial
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-006562-15 Sponsor Protocol Number: FFU111439 Start Date*: 2008-03-28
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110m...
    Medical condition: Perennial Allergic Rhinitis (PAR) in adults and children of 12 years and older.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034382 Perennial allergic rhinitis LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed) HU (Completed) SK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002248-95 Sponsor Protocol Number: BOFT-0418-SAFE Start Date*: 2018-09-26
    Sponsor Name:FAES FARMA S.A.
    Full Title: Multi-centre, randomised, double blind, placebo-controlled, parallel, phase III study to assess the safety, tolerability and efficacy of bilastine ophthalmic solution 0.6% in adults
    Medical condition: Allergic Conjunctivitis (AC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001709 Allergic conjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) HU (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-000617-20 Sponsor Protocol Number: SMART_2 Start Date*: 2013-08-23
    Sponsor Name:Lofarma S.p.A.
    Full Title: A Dose Finding Study of the Efficacy of LAIS® Mites Sublingual tablets in patients suffering from house dust mite-induced allergic rhinoconjunctivitis A prospective, double-blind, placebo-controlle...
    Medical condition: Patients suffering from allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000414-11 Sponsor Protocol Number: 603-PG-PSC-191 Start Date*: 2012-08-31
    Sponsor Name:LETI Pharma GmbH
    Full Title: Multicenter, placebo-controlled, long-term study of Depigoid Birch 5000 in adults and adolescents with allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma
    Medical condition: Seasonal allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma due to birch pollen allergy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10066093 Birch pollen allergy LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) CZ (Completed) FI (Completed) PL (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2008-008448-26 Sponsor Protocol Number: 603-PG-PSC-173 Start Date*: 2009-10-20
    Sponsor Name:LETI Pharma GmbH
    Full Title: Randomized, double-blind, parallel group, multicenter study to evaluate the efficacy and safety of four doses of depigmented glutaraldehyde polymerized birch pollen allergenic extract (Depigoid® Bi...
    Medical condition: Allergic rhinitis and/or rhinoconjunctivitis, with or without intermittent asthma, caused by birch pollen.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001723 Allergic rhinitis LLT
    9.1 10039097 Rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000576-13 Sponsor Protocol Number: INO102141 Start Date*: 2004-11-03
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A two-centre, randomised, double-blind, double-dummy, placebo-controlled, 3-period cross-over study to evaluate the effect of treatment with repeat doses of GW274150 on the allergen-induced late as...
    Medical condition: Mild asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002844-18 Sponsor Protocol Number: 04071962 Start Date*: 2017-01-16
    Sponsor Name:Medical University of Vienna, Dpt. of Pediatrics
    Full Title: Preventive sublingual immunotherapy for house dust mite sensitized preschool children
    Medical condition: Patients; children at age 4 years with house dust mite IgE sensitization without allergic disease
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003533-10 Sponsor Protocol Number: CIGE025ABR01 Start Date*: 2016-02-16
    Sponsor Name:Novartis
    Full Title: A Randomized, Open-label, Multicenter Study to Evaluate the Effect of Xolair (Omalizumab) as Add-on Therapy to Inhaled Corticosteroid + Long-Acting Beta Agonist in Fixed or Flexible Dosing Compared...
    Medical condition: Severe persistent allergic asthma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-000091-14 Sponsor Protocol Number: FFR102123 Start Date*: 2004-09-17
    Sponsor Name:GlaxoSmithKline, S.A
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre, Long-Term Study to Evaluate the Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg ...
    Medical condition: Perennial allergic rhinitis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) LV (Completed) LT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001822-89 Sponsor Protocol Number: SMART_1_2012 Start Date*: 2012-08-21
    Sponsor Name:Lofarma S.p.A.
    Full Title: A Dose Finding Study of the Efficacy of LAIS® Birch-Alder tablets in patients suffering from tree pollen-induced allergic rhinoconjunctivitis
    Medical condition: Patients suffering from allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000006-32 Sponsor Protocol Number: IXR-203-30-204 Start Date*: 2005-06-13
    Sponsor Name:IVAX RESEARCH, INC.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, DOSE RANGING STUDY TO DETERMINE THE EFFICACY AND SAFETY OF AN INVESTIGATIONAL INTRANASAL CORTICOSTEROID COMPARED TO PLACEBO AND OPEN-LABEL FLUTICASONE PR...
    Medical condition: Perennial (persistant) Allergic Rhinitis
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 16:51:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA